No Data
No Data
Is Now The Time To Put United Therapeutics (NASDAQ:UTHR) On Your Watchlist?
Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $350
Wells Fargo analyst Tiago Fauth maintains $United Therapeutics(UTHR.US)$ with a buy rating, and maintains the target price at $350.According to TipRanks data, the analyst has a success rate of 38.8%
Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)
Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $344
Leerink Partners analyst Roanna Ruiz maintains $United Therapeutics(UTHR.US)$ with a buy rating, and adjusts the target price from $338 to $344.According to TipRanks data, the analyst has a success
United Therapeutics Insider Sold Shares Worth $2,355,544, According to a Recent SEC Filing
Martine A Rothblatt, Director, Chairperson & CEO, on July 15, 2024, sold 7,200 shares in United Therapeutics (UTHR) for $2,355,544. Following the Form 4 filing with the SEC, Rothblatt has control
Why United Therapeutics (UTHR) Is a Top Growth Stock for the Long-Term
Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company.
151652693 : There are many theories that do not touch the QE factor that caused the rise and harvest of global finance
151336027 :
151830249 :
151078437 :
151817588 :
View more comments...